Products for Research Use Only
RegisterLogin

Ipidacrine-d9

CAT: 0804-HY-W027553S1Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W027553S1Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ipidacrine-d9 (NIK-247-d9 (free base) ) is the deuterium labeled Ipidacrine. Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K+ and Na+-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases[1][2][3][4][5].
Product Name Alternative
NIK-247-d9 (free base)
UNSPSC
12352005
Target
Cholinesterase (ChE) ; Isotope-Labeled Compounds; Potassium Channel; Sodium Channel
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling; Others
Field of Research
Metabolic Disease
Smiles
[2H]C1(C2=C(C([2H])(C([2H])(C1([2H])[2H])[2H])[2H])N=C3C([2H])(CCC3=C2N)[2H])[2H]
Molecular Formula
C12H6D10N2
Molecular Weight
198.33
References & Citations
[1]Kojima J, et al. Ipidacrine (NIK-247) : A Review of Multiple Mechanisms as an Antidementia Agent[J]. CNS Drug Reviews, 1998, 4 (3) : 247-259.|[2]Pulatov S S. Efficacy of ipidacrine in the recovery period of ischaemic stroke[J]. World Bulletin of Public Health, 2022, 7: 28-32.|[3]Bykov V, et al. Ipidacrine (Axamon), A Reversible Cholinesterase Inhibitor, Improves Erectile Function in Male Rats With Diabetes Mellitus-Induced Erectile Dysfunction[J]. Sex Med. 2022 Feb;10 (1) :100477.|[4]Zinovyeva O E, et al. Ipidacrine efficacy in diabetic polyneuropathy complex treatment: A review[J]. Consilium Medicum, 2022, 24 (2) : 123-127.|[5]Samartsev I N, et al. The efficacy and safety of ipidacrine in patients with idiopathic neuropathy of the facial nerve (PELICAN study) [J]. Neurology, Neuropsychiatry, Psychosomatics, 2022, 14 (1) : 60-68.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-W027553-01Ipidacrine
HY-W027553R-01Ipidacrine (Standard)
HY-B1355AS-01Oxyphenbutazone-d9
HY-B1431S2Butylparaben-d9
HY-B0552SDibucaine-d9
HY-131105S-01Cimbuterol-d9
HY-127035S4-01Tristearin-d9
HY-17007SSaquinavir-d9
HY-N0437S-01Progesterone-d9
HY-131104SBrombuterol-d9

Alternative Products

CatalogName
TRC-I739332-2.5MGIpidacrine-d9 (Major)
BA8469-1000Ipidacrine
CS-O-64054Ipidacrine-d6
M16471-01Ipidacrine hydrochloride
452443-01Ipidacrine Hydrochloride Hydrate
C183201Carboxytolbutamide-d9 (butyl-d9)
MBS6049828-01Docetaxel-d9 (Taxotere-d9)

Popular Products